<?xml version="1.0" encoding="UTF-8"?>
<p>Host-targeted small molecules approved for other human diseases may modulate the virus-host interactions of SARS-CoV-2. Chloroquine, a potential broad-spectrum antiviral drug 
 <xref rid="B25" ref-type="bibr">25</xref>, 
 <xref rid="B26" ref-type="bibr">26</xref>, was shown by a recent study had anti-SARS-CoV-2 activity 
 <xref rid="B20" ref-type="bibr">20</xref>. Its clinical efficacy is under study in an open-label trial (ChiCTR2000029609) 
 <xref rid="B12" ref-type="bibr">12</xref>. IFNα (5 million U) atomization inhalation was recommended as antiviral therapy to treat SARS-CoV-2 
 <xref rid="B16" ref-type="bibr">16</xref>. A trial testing IFNα-2b combination of the approved anti-HCV inhibitors has been initiated 
 <xref rid="B17" ref-type="bibr">17</xref>, however, whether it could act synergistically against SARS-CoV-2 is unclear.
</p>
